Associated Papers
Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.
Vanwong N et al.
Pharmacogenomics and Personalized Medicine, 2022
Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations.
Li X et al.
Pharmacogenomics and Personalized Medicine, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
Yang F et al.
Scientific Reports, 2018
Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population.
Cai LL et al.
Scientific Reports, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
Nassif A et al.
Radiology, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC et al.
British Journal of Clinical Pharmacology, 2012
Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population.
Chae YJ et al.
Journal of Pharmaceutical Sciences, 2012
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
Clarke JD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3.
Glaeser H et al.
British Journal of Pharmacology, 2010
Pharmacogenetics of membrane transporters: an update on current approaches.
Sissung TM et al.
Molecular Biotechnology, 2010
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Hamada A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM et al.
Methods in Molecular Biology (clifton, N.j.), 2008
Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.
Mahagita C et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology, 2007
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Smith NF et al.
Clinical Pharmacology and Therapeutics, 2007
Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1.
Hänggi E et al.
Molecular Pharmacology, 2006
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
Letschert K et al.
Pharmacogenetics, 2004
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0